ArticleExperimental and therapeutic medicine2022
TMEM14A aggravates the progression of human ovarian cancer cells by enhancing the activity of glycolysis.
Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- TMEM44 as a Novel Prognostic Marker for Hepatocellular Carcinoma is Associated with Tumor Invasion, Migration, and Apoptosis.Biochemical genetics · 2026Article
- The SLC-ome of membrane transport: From molecular discovery to physiology and clinical applications.Physiological reviews · 2025Review
- TMEM71 is crucial for cell proliferation in lower-grade glioma and is linked to unfavorable prognosis.Cancer cell international · 2025Article
- The emerging role of transmembrane proteins in tumorigenesis and therapy.Translational cancer research · 2025Review
- Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma.Scientific reports · 2025Article
- TMEM33, an oncogene regulated by miR-214-3p, promotes the progression of lung adenocarcinoma through the Wnt/β-catenin signaling pathway.Oncology research · 2025Article
- NNT-AS1, A Long Non-coding RNA with Therapeutic Promise in Mycoplasma Pneumoniae Pneumonia via the Mir-410-3p/TMEM14A/Wnt/ΒCatenin Signalling Pathway.Iranian journal of biotechnology · 2025Article
- TMEM211 Promotes Tumor Progression and Metastasis in Colon Cancer.Current issues in molecular biology · 2023Article
- Landscape of Druggable Molecular Pathways Downstream of Genomic CDH1/Cadherin-1 Alterations in Gastric Cancer.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OV) affects hundreds of thousands of women worldwide each year. The delayed onset of symptoms and insufficient diagnostic options of OV are mainly responsible for its high mortality rate and poor prognosis in the patients. Transmembrane (TMEM) proteins are associated with human cancers, and multiple of them have been identified as oncogenic. TMEM14A is among this group. However, the function of TMEM14A in OV remains unclear. In the present study, it was aimed to find out the roles and underlying mechanism of TMEM14A in OV. RNA interference and lentiviral-mediate vector were used to induce TMEM14A silencing or overexpression. Flow cytometric analysis was used to examine cell apoptosis. Oxygen consumption and extracellular acidification were determined using Seahorse XF24 analyzer. Xenograft mice model was constructed to quantify the role of TMEM14A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.